Product
H3B-6545
Aliases
H3B-6545 (150, 300, 450 mg)
3 clinical trials
10 indications
Indication
Breast NeoplasmsIndication
Breast CancerIndication
CancerIndication
BreastIndication
Estrogen Receptor Positive TumorIndication
estrogen receptor positiveIndication
ReceptorsIndication
OestrogenIndication
GeneIndication
ERBB2Clinical trial
A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast CancerStatus: Completed, Estimated PCD: 2023-10-26
Clinical trial
A Phase 1 Study of H3B-6545 in Japanese Women With Estrogen Receptor-positive, HER2 Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-31
Clinical trial
An Open-Label Multicenter Phase 1b Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive HER2-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-09-16